The Central Data Repository (CDR) is a publicly accessible resource providing an overview of clinical research studies, sites and networks working on infectious diseases with epidemic or pandemic potential in Europe. It helps researchers and other stakeholders identify relevant research activities and support collaboration across Europe.
Why was the CDR developed?
The CDR was launched under the EU-funded VERDI (GA-101045989) project, and further developed as part of the EU-funded CoMeCT (GA-101136531) and PIPELINE (GA-101155852) projects. It provides an accessible, browsable overview of the European clinical research aiming to facilitate collaboration and data sharing, and help avoid duplication of research efforts. By connecting studies with the sites and networks involved, the CDR supports the identification of relevant research expertise and infrastructure, which can contribute to a more coordinated response to emerging infectious disease threats.
What is included in the CDR?
The CDR brings together three interconnected types of information:
Studies: The CDR includes cohort studies (CSs) and randomised controlled trials (RCTs), including adaptive platform trials (APTs). To be included, studies must investigate a selected infectious disease or pathogen, have at least one clinical site in Europe, and have had active participant enrolment on or after 1 January 2022. Each study is named by its acronym, or if unavailable, the first author of the study. Mappings have been completed for the below pathogens and syndromes, while several additional studies have been submitted directly by investigators:
- SARS-CoV-2 treatment (CSs, RCTs)
- Post COVID-19 condition (CSs, RCTs)
- Avian influenza A(H5N1) virus (CSs, RCTs)
- Respiratory syncytial virus (CSs)
- Influenza-like illness/acute respiratory infection (CSs)
- Monkeypox virus (CSs)
- Chikungunya virus (CSs)
- Dengue virus (CSs)
- Zika virus (CSs)
- West Nile virus (CSs)
- Chlamydia trachomatis (CSs)
- Neisseria gonorrhoeae (CSs)
Networks: The CDR includes European clinical research networks, organisations or projects that coordinate multiple sites conducting clinical trials and/or cohort studies on infectious diseases with epidemic or pandemic potential. The CDR includes networks operating nationally within a European country or across multiple countries. The network sites, descriptions and websites have been provided directly by the network coordinators.
Sites: The CDR includes European clinical research sites conducting clinical trials and/or cohort studies on infectious diseases with epidemic or pandemic potential. A site can be assinged to a study, from a publication or study record, or submited by the network coordinator. Therefore a site can be included in the CDR even if no associated study has yet been included.
How is information collected for the CDR?
Studies are identified across several publicly available sources (PubMed, Scopus, ECRIN MDR, CTIS, ClinicalTrials.gov). AI-assisted tools support study screening and metadata extraction under expert supervision. Study information is reviewed and organised using curated descriptors (tags) to support consistent classification, browsing and filtering. Sites and networks are identified from study publications and records, as well as from information provided directly by researchers. Site names are standardised and matched to identifiers in the Research Organization Registry (ROR) where possible.
How to use the CDR
1. Choose a view
Start with Studies to explore clinical research activities, or Sites to explore research locations and their associated studies and networks.
2. Search and filter
Use the available search and filtering options to find information relevant to your interests.
3. Open an ID Card
Select a study or site to view its available information.
4. Explore the connections
Follow links between Study, Site and Network ID Cards to discover related information.
About the data
The CDR is a developing resource and mapping is an ongoing, cumulative process. The pathogens and syndromes selected for mapping to date have been in accordance with the European epidemiological situation and stakeholder requests. The mapping of sites and networks is a recent extension of the CDR and is at an initial stage. The current content provides an overview of studies, sites and networks identified so far and their available connections. Coverage, information and links will be progressively expanded and refined. The CDR is not an exhaustive inventory of all clinical research studies, sites or networks in Europe. The absence of a record, or of a link between records, does not necessarily mean that the study, site, network or relationship does not exist.
Use of Artificial Intelligence
AI forms part of the methodology employed for mapping studies from resources (BioLinkBERT screening, Gemma 3 extraction). All data presesnted on the CDR are expert-verified.
Get in touch
We welcome collaboration with other initiatives working in this area. If you are interested in collaborating, have information to contribute, or notice an error, omission, duplicate record or incorrect link in the CDR, please contact us. Feedback from CDR users helps improve the coverage and quality of the repository.
Terms and conditions
The CDR is a platform constructed to provide an overview of the studies running in Europe. While the data is provided in good faith and to the best of our knowledge, neither UNIVR nor any VERDI/COMECT partners make any warranty, express or implied, including warranties of fitness for a particular purpose, or assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information provided (either isolated or in the aggregate), or represents that its use would not infringe privately owned rights.
The data is intended for Educational and Research purposes only. The term Educational Purposes means* (i) in the case of a Qualified Educational Institution, Faculty or Other Authorized Educational Licensees, purposes directly related to learning, teaching, and training, that are part of the instructional functions performed by a Qualified Educational Institution or Other Authorized Educational Licensee and (ii) in the case of an individual, purposes related to learning and training. “Educational Purposes” does not include research, commercial, professional, or any other for-profit purposes.
Legend
Fragile population
Individuals who are more vulnerable to poor health outcomes due to factors like chronic illness, weakened immune systems, disabilities or socioeconomic disadvantages
General population
Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population
Healthcare workers
A professional providing medical care, support, or public health services in various healthcare settings
Immunocompromised host
An individual with an impaired immune system due to conditions such as HIV, cancer, organ transplantation, or immunosuppressive therapy
Men who have sex with men
Men who have sex with men are men who engage in sexual activity with other men, regardless of their sexual orientation or sexual identity
People at high risk of STIs
Individuals with an increased likelihood of acquiring sexually transmitted infections (STIs) due to behavioral, biological, or social factors
People living with HIV
Individuals who have been diagnosed with human immunodeficiency virus (HIV) and may be receiving antiretroviral therapy to manage the condition
PrEP users
Individuals who take pre-exposure prophylaxis (PrEP), a medication regimen to prevent HIV infection
Community
A research environment where studies are conducted outside of clinical or laboratory settings, focusing on real-world populations
Hospital
Encompassing all units and departments within a hospital setting
Infectious diseases unit
Hospital ward specialised in infectious diseases
Intensive care unit
Hospital intensive care unit (ICU) ward
Long-term care facility
A healthcare institution that provides continuous medical and personal care
Non-hospital health centre
Healthcare facilities outside hospitals, such as long term care facilities, community health centers, and vaccination centers
Outpatient clinic
A healthcare facility where patients receive medical care, consultations, or treatments without being admitted to a hospital
Primary care
The first level of healthcare, including general medical services, such as family medicine
STD/STI clinic
A specialized healthcare facility that provides testing, diagnosis, treatment, and counseling for sexually transmitted diseases (STDs) and infections (STIs)
Telemedicine
The remote delivery of healthcare services using digital technology
Vaccination centre
A healthcare facility or designated location where vaccines are administered to individuals. It may operate in hospitals, clinics, pharmacies, or temporary sites for mass immunization campaigns
Antineoplastic agent
Drugs used to inhibit or stop the growth of cancer cells. Examples include chemotherapy, targeted therapy, and immunotherapy agents
Antivirals
A class of medications used to treat viral infections
Dietary
A type of lifestyle intervention that aims to change a patient's diet
Immunomodulator
Drugs used to modify the immune system's response, either by enhancing or suppressing it
Lifestyle
Interventions striving to intoduce a permanent change in the patient's lifestyle. Examples include changes to excercise routine, diet or sleep
Non pharmacological intervention
All types of intervention that are not pharmacological, not including diagnostic
Pharmacological intervention
This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents
Probiotic
Pharmacological compounds aimed at the modification of the gut microbiome
Rehabilitation
All non-pharmacological interventions based on physical or cognitive rehabilitation of the patient
Statins
Class of medications that lower cholesterol levels